Literature DB >> 16472361

Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.

Janusz K Rybakowski1, Alina Borkowska, Maria Skibinska, Aleksandra Szczepankiewicz, Pawel Kapelski, Anna Leszczynska-Rodziewicz, Piotr M Czerski, Joanna Hauser.   

Abstract

The measures of prefrontal cognition have been used as endophenotype in molecular-genetic studies. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive functions and in the pathogenesis of major psychoses. This study investigates the relationship between Val66Met polymorphisms of the BDNF gene and prefrontal cognitive function in 129 patients with schizophrenia and 111 patients with bipolar mood disorder. Cognitive tests included the Wisconsin Card Sorting Test (WCST), with such domains as number of perseverative errors, non-perseverative errors, completed corrected categories, conceptual level responses, and set to the first category, and the N-back test, where mean reaction time and percent of correct reactions were measured. Genotyping for Val66Met BDNF polymorphism was done by polymerase chain reaction method. In schizophrenia, no relationship between Val66Met polymorphism of the BDNF gene and the results of the WCST was observed. Patients with Val/Val genotype had a higher percentage of correct reactions in the N-back test than those with the remaining genotypes. Bipolar patients with Val/Val genotype obtained significantly better results on three of five domains of the WCST. No relationship between BDNF polymorphism and the results of the N-back test was found in this group. A limitation to the results could be variable psychopathological state and medication during cognitive testing and lack of Hardy-Weinberg equilibrium in schizophrenia group. Val66Met polymorphism of the BDNF gene may be associated with cognitive performance on the WCST in bipolar mood disorder but not in schizophrenia. An association of this polymorphism with performance on the N-back test in schizophrenia and not in bipolar illness may suggest that in schizophrenia, the BDNF system may be connected with early phases of information processing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472361     DOI: 10.1111/j.1440-1819.2006.01462.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  34 in total

1.  [In memory of Lev L'vovich Kiselev].

Authors:  A A Bogdanov; V G Debabov
Journal:  Mol Biol (Mosk)       Date:  2008 Sep-Oct

2.  The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis.

Authors:  Yu Pei; Alicia K Smith; Yongjun Wang; Yanli Pan; Jian Yang; Qi Chen; Weigang Pan; Feng Bao; Lisha Zhao; Changle Tie; Yizheng Wang; Jian Wang; Wenfeng Zhen; Jinxia Zhou; Xin Ma
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-18       Impact factor: 3.568

Review 3.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

Review 4.  Brain-derived neurotrophic factor: its impact upon neuroplasticity and neuroplasticity inducing transcranial brain stimulation protocols.

Authors:  L Chaieb; A Antal; G G Ambrus; W Paulus
Journal:  Neurogenetics       Date:  2014-02-25       Impact factor: 2.660

Review 5.  Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics.

Authors:  Iva Dincheva; Charles E Glatt; Francis S Lee
Journal:  Neuroscientist       Date:  2012-02-24       Impact factor: 7.519

6.  The BDNF Val66Met polymorphism modulates sleep intensity: EEG frequency- and state-specificity.

Authors:  Valérie Bachmann; Carina Klein; Sereina Bodenmann; Nikolaus Schäfer; Wolfgang Berger; Peter Brugger; Hans-Peter Landolt
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

7.  Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.

Authors:  Weihong Lu; Chen Zhang; Zhenghui Yi; Zezhi Li; Zhiguo Wu; Yiru Fang
Journal:  J Mol Neurosci       Date:  2012-04-03       Impact factor: 3.444

8.  Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration.

Authors:  Kamilla Miskowiak; Becky Inkster; Ursula O'Sullivan; Sudhakar Selvaraj; Guy M Goodwin; Catherine J Harmer
Journal:  Exp Brain Res       Date:  2007-09-08       Impact factor: 1.972

9.  Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.

Authors:  Ilja Spellmann; Norbert Müller; Richard Musil; Peter Zill; Anette Douhet; Sandra Dehning; Anja Cerovecki; Brigitta Bondy; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03-17       Impact factor: 5.270

10.  Population genetic study of the brain-derived neurotrophic factor (BDNF) gene.

Authors:  T L Petryshen; P C Sabeti; K A Aldinger; B Fry; J B Fan; S F Schaffner; S G Waggoner; A R Tahl; P Sklar
Journal:  Mol Psychiatry       Date:  2009-03-03       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.